tbuckley/cabot-search huggingface dataset:
137P Repurposing drug screen of patient-derived malignant pleural mesothelioma cells reveals potential anti-cancer activity
Authors: A. Laure, A. Rigutto, M. Manovah, M. Chambon, G. Turcatti, M. Kirschner, I. Opitz, S. Hiltbrunner, A. Curioni-Fontecedro
Journal: Journal of Thoracic Oncology (2023)
84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
Authors: P.M. Forde, J. Spicer, N. Girard, M. Provencio, S. Lu, C. Wang, M. Awad, T. Mitsudomi, E. Felip, S.J. Swanson, G. Saylors, K-N. Chen, F. Tanaka, P. Tran, N. Hu, J. Cai, J. Bushong, J. Neely, D. Balli, S.R. Broderick
Journal: Journal of Thoracic Oncology (2023)
104TiP MRD Evaluation of aumolertinib in EGFR mutation-positive stage IB and stage IA2–3 NSCLC after complete surgical resection: A multicenter, open-label, single-arm study (ASSIST)
Authors: C. Cheng, H. Li, J. Zhang, X. Ben, S. Li, D. Wang, W. Lin, W. Lv
Journal: Journal of Thoracic Oncology (2023)
169P Phase I dose escalation trial combining olaparib and thoracic radiation therapy in extensive-stage small cell lung cancer
Authors: A. Rimner, B. Lok, D.Y. Gelblum, R.R. Kotecha, F. Albrecht, J.Y. Shin, Q. Laplant, A. Namakydoust, A. Shepherd, D. Gomez, N. Shaverdian, A. Wu, C.B. Simone, H.A. Yu, K. Ng, R. Daly, M.D. Offin, M. Ginsberg, Z. Zhang, C.M. Rudin
Journal: Journal of Thoracic Oncology (2023)
152P Role of occupation in patients with non-small cell lung cancer (NSCLC) in Spain: Data from the SCAN study
Authors: J.C. Laguna Montes, F. Turrisi, V. Albarran, L. Gonzalez-Aguado, T. Gorría Puga, I. Nalda Ariza, B. Pastor, M. Potrony, M. Garcia De Herreros, F.J. Muñoz i Carrillo, O. Castillo, P. Blasco, R. Reyes, N. Viñolas, S. Hijazo-Pechero, X. Sole, A. Arcocha, C. Teixido, N. Reguart, L. Mezquita
Journal: Journal of Thoracic Oncology (2023)
155P Eligibility for lung cancer screening among patients diagnosed with lung cancer in Greece
Authors: M.I. Anagnostakis, E. Panagiotou, N. Salonitis, A. Skoura, D. Setatoglou, A. Karachaliou, N. Syrigos, L. Stournara, M. Mani, I. Vathiotis
Journal: Journal of Thoracic Oncology (2023)
101P Evidence base for exercise prehabilitation suggests favourable outcomes for patients undergoing surgery for non-small cell lung cancer despite being of low therapeutic quality: A systematic review and meta-analysis
Authors: M. Voorn, V.E.M. van Kampen-van den Boogaart, G. Bootsma, B. Bongers, R. Franssen, T. Hoogeboom
Journal: Journal of Thoracic Oncology (2023)
128P Stereotactic ablative radiotherapy in locally-advanced non-small cell lung cancer patients: Little palliation or big cure? Sub-analysis of START-NEW-ERA phase II trial
Authors: F. Arcidiacono, M. Casale, E. Maranzano, M. Italiani, S. Fabiani, C. Zannori, B. Enrico, A. Guida, F. Trippa, P. Anselmo
Journal: Journal of Thoracic Oncology (2023)
33P Real-world experience of MET TKI-induced peripheral edema
Authors: R. Ferrara, J.F. Vansteenkiste, X. Yang, F. Grossi, B. Melosky, M-J. Ahn, A. Calles, O.S.H. Chan, B. Han, V.R. Bulusu, R. Califano, K. Nishino, V. Ghori, P. Ronga, K. Berghoff, S. Vlassak, X. Le
Journal: Journal of Thoracic Oncology (2023)
21P Bevacizumab plus atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR tyrosine kinase inhibitor: The BACH-NET study
Authors: G. Pasello, M. Lorenzi, G. Crivellaro, E. Capelletto, S. Butticè, F. Perrone, M. Tiseo, V. Scotti, V. Polo, A. Favaretto, M. Montrone, R. Berardi, F. Zustovich, L. Toschi, A. Bearz, M. Milella, S. Frega, L. Bonanno, V. Guarneri
Journal: Journal of Thoracic Oncology (2023)
15MO Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib
Authors: M. Hoejgaard, A. Drilon, J.J. Lin, S. Kummar, D.S.W. Tan, J. Patel, S. Leyvraz, V. Moreno Garcia, L.S. Rosen, B. Solomon, J. Yachnin, Y. Liu, M-S. Dai, R. Norenberg, D-I. Burcoveanu, L. Yun, G. Beckmann, C.E. Mussi, L. Shen
Journal: Journal of Thoracic Oncology (2023)
95P Neoadjuvant treatment pattern and association between real-world event-free survival (rwEFS) and overall survival (OS) in patients (pts) with resected early-stage non-small cell lung cancer (eNSCLC)
Authors: J. Donington, X. Hu, S. Zhang, Y. Song, C. Gao, A. Arunachalam, D. Chirovsky, A. Lerner, A. Jiang, J. Signorovitch, A. Samkari
Journal: Journal of Thoracic Oncology (2023)
223P Surgery versus bronchoscopic cryotherapy for the treatment of lung carcinoid tumors: An overview of 5-year experience
Authors: F.S. Caushi, D.F. Xhemalaj, I. Skenduli, H. Hafizi, S. Bala, O. Nuredini, A. Hatibi, E. Shima
Journal: Journal of Thoracic Oncology (2023)
221P Comparison of efficacy and safety of carboplatin combined with nab-paclitaxel or paclitaxel as first-line therapy for advanced thymic epithelial tumors
Authors: Y. Hao, J. Si, J. Wei, X. Gu, W. Wang, Y. Zhang, Y. Guan, H. Huang, C. Xu, Z. Song
Journal: Journal of Thoracic Oncology (2023)
20P Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small cell lung cancer with central nervous system metastases in a multi-center, phase II umbrella trial (CTONG1702)
Authors: S-Y.M. Liu, Q. Zhou, C. Lu, J-Y. Deng, Z. Wang, Y-S. Li, M-M. Zheng, B-F. Xu, X-R. Dong, Y-Y. Du, J-W. Cui, Q. Chu, X-Y. Bai, Y-L. Sun, A. Li, C-R. Xu, B-C. Wang, H-J. Chen, J-J. Yang, Y-L. Wu
Journal: Journal of Thoracic Oncology (2023)
215P Assessment of patient and clinician awareness and clinical outcomes of changes in lifestyle habits during lung cancer treatment
Authors: A.I. Martin Quesada, A. Padilla, M.G. Gordo, P.R. Hernaez, A. Herrero Márquez, L. Herrera Gorrín, A. Cardena, C. Dorta Pérez, M.L. Soriano Tabares, C. Hernandez Perez, M. Morales-Gonzalez
Journal: Journal of Thoracic Oncology (2023)
94P Neoadjuvant tislelizumab combined with (nab)-paclitaxel plus platinum-based chemotherapy for patients with stage IIA–IIIB squamous NSCLC: A real-world retrospective study
Authors: X. Huang, Z. Mao, B. Li, M. Hu, P. Wang, L. Ding
Journal: Journal of Thoracic Oncology (2023)
187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)
Authors: B. Sierra-Rodero, C. Martínez-Toledo, M. Molina-Alejandre, V. Calvo, E. Nadal, B. Massuti Sureda, R. García Campelo, C. Gonzalez Ojea, A. Martinez-Marti, M. Domine Gomez, S. Ponce Aix, M.A. Insa Molla, J. De Castro Carpeno, M. Majem, I.C. Barneto Aranda, D. Rodriguez-Abreu, E. del Barco, M. Cobo Dols, M. Provencio Pulla, A. Cruz-Bermudez
Journal: Journal of Thoracic Oncology (2023)
26P Real-world use of tyrosine kinase inhibitors (TKI) in epidermal growth factor receptor mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) in nine countries
Authors: J. Samol, I. Demedts, M. Erman, V. Kozlov, J.N. Minatta, F.V. Moiseenko, M.S. Paats, S.J. Rajappa, T. Bailey, H. Wallis, M. Madondo, D. Kahangire, M. Zukin
Journal: Journal of Thoracic Oncology (2023)
113P Clinical overstaging in pathologic stage I non-small cell lung cancer: Prognostic implications
Authors: N.O.T. Deboever, M. Eisenberg, W.L. Hofstetter, R. Mehran, R. Rajaram, D. Rice, S. Swisher, G. Walsh, A. Vaporciyan, B. Sepesi, M. Antonoff
Journal: Journal of Thoracic Oncology (2023)
125P Real-world treatment patterns in stage III NSCLC patients: Interim results of a prospective, multicenter, non-interventional study (MOOREA)
Authors: L. Xing, J. Yu, R. Zhao, W. Yang, Y. Guo, J. Li, C. Xiao, Y. Ren, L. Dong, D. Lv, L. Zhao, Y. Lin, X. Zhang, L. Chen, A. Zhang, Y. Wang, D. Jiang, A. Liu, C. Ma
Journal: Journal of Thoracic Oncology (2023)
160P Non-invasive analysis of VOCs in exhaled air can distinguish healthy controls from lung cancer patients and may improve the effectiveness of lung cancer screening
Authors: S. Hulo, J. Jacques, F. Sihrener, E. Wasielewski, L. Jourdan, G. Poslednik, C. Poulet, A. Turlotte, T. Gey, Y. Douadi, L. Thiberville, M. Dewolf, J-M. Lecerf, I. Estevié, V. Ricard, J. Martin, A-C. Romain, N. Locoge, R. Matran, A. Scherpereel
Journal: Journal of Thoracic Oncology (2023)
153P Molecular epidemiology of EGFR mutations in NSCLC: A single-center experience from India
Authors: M. Ghosh, Y. Shivakumar, G. Balaram, R. Thomas, B. Dharman, P.V. Kowsik, S.N. Ghorpade, T.B. Nanjaiah, S. Patil, R. Naik, G.B. Kanakasetty, S.C. Thungappa, S.H. Poppareddy, S. Belagutti Jayappa, S. Bhattacharjee, S. Papaiah Susheela, M. Naseer R, A. Sharma, P.P. Gunari, B.S. Ajaikumar
Journal: Journal of Thoracic Oncology (2023)
71P Biomarker analysis from phase I/II study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)
Authors: A. Gazzah, J.S. Lee, E. Wang, N. Ternès, H. Wang, E. Boitier, A. Lartigau, M. Chadjaa, C. Dib, G. Muzard, S. Valence, A. Remaury, C.C. Palu, A-L. Bauchet
Journal: Journal of Thoracic Oncology (2023)
171P Comparison of etoposide/cisplatin and irinotecan/cisplatin for extensive-stage small cell lung cancer in Koreans: A real-world retrospective observational study
Authors: E. Lee, S.S. Yoo, S.H. Choi, H. Seo, S.Y. Lee, S.I. Cha, C.H. Kim, J.Y. Park
Journal: Journal of Thoracic Oncology (2023)
74P Non-small cell lung cancer (NSCLC) predictors of response to immunotherapy (ICI): LIPI index and immune-related toxicity
Authors: A. Moratiel Pellitero, R. Lastra, M. Zapata García, M. Zurera Berjaga, I. Ruiz Moreno, A. Goás Gómez, M. Martí Pi, A. Romero Monleón, K. Osorio, M. Arribas Velasco, S. Esteras Per, M. Gascon Ruiz, A. Sesma Goñi, E. Quilez Bielsa, M.D. Isla Casado
Journal: Journal of Thoracic Oncology (2023)
100P Effects of U.S. insurance type on 5-year all-cause mortality after robotic-assisted pulmonary lobectomy for lung cancer
Authors: A.O. Dumitriu Carcoana, J. Singh, J.A. Malavet, J.C. Marek, K.M. Labib, W.N. Doyle, W.J. West, P. Deol, C.C. Moodie, J.R. Garrett, J.J-A.R. Baldonado, J.R. Tew, J.P. Fontaine, E. Toloza
Journal: Journal of Thoracic Oncology (2023)
Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis
Authors: Sang-Hyup Lee, Yong-Joon Lee, Jung Ho Heo, Seung-Ho Hur, Hyun Hee Choi, Kyung-Jin Kim, Ju Han Kim, Keun-Ho Park, Jung Hee Lee, Yu Jeong Choi, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim
Journal: Journal of the American College of Cardiology (2023)
161O RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)
Authors: C.M. Rudin, A. Dowlati, Y. Chen, A.F. Navarro Mendivil, J.C-H. Yang, G. Stojanovic, P. Rich, Z.G. Andric, Y-L. Wu, H. Chen, L. Zhang, S. Yeung, F.M. Benzaghou, L. Paz-Ares, P.A. Bunn
Journal: Journal of Thoracic Oncology (2023)
222P Thoracic neuroendocrine tumors: Experience in a third level hospital in Mexico
Authors: R.F. Riera Sala, A.K. Dip Borunda, A.E. Martin Aguilar, M. Aguilera Bailon, B.L. Rubio Anguiano, L. Hernández Hoil, A.A. Pimentel Rentería, A.O. Orzuna Vázquez, R.C. Grajales, R. Medrano Guzmán
Journal: Journal of Thoracic Oncology (2023)
73P Qualitative research to evaluate perceptions around biomarker testing and patient-reported outcomes (PROs) for use in studies of non-small cell lung cancer (NSCLC)
Authors: M.K. Horn, S.D. Mathias, H. Colwell, A.C. Heerdegen, K. Bevans, T. Li, A. Stevens, J. Sermon, J. Fastenau, R. Pierson
Journal: Journal of Thoracic Oncology (2023)
12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study
Authors: N. Reinmuth, B.C. Cho, A. Luft, J.A. Alatorre Alexander, S. Lucien Geater, K. Laktionov, S-W. Kim, G. Ursol, M. Hussein, F.L. Lim, C-T. Yang, L.H. Araujo, H. Saito, K. Barrett, C. Lowery, R. Tattersfield, S. Peters, E.B. Garon, T.S.K. Mok, M.L. Johnson
Journal: Journal of Thoracic Oncology (2023)
47P Timing of radiotherapy affects outcomes of patients with metastatic NSCLC who receive immunotherapy
Authors: S. Li, J.V. Inampudi, H.R. Koshiya, J.M. Patel, N.E. Wiest, T.S. Pai, E.B. Butts, B.J. McKinley, J. Wang, G. Sacchi de Camargo Correia, O.M. Mosalem, R. Manochakian, Y. Zhao, Y. Lou
Journal: Journal of Thoracic Oncology (2023)
151P Molecular epidemiology and real-world outcomes of genomically-matched non-squamous non-small cell lung cancer (nsNSCLC) patients in a diverse Brazilian population
Authors: R. Dienstmann, T. Montella, F. Orpinelli, R.D. Paes, P.R. De Marchi, F.C. Koyama, C.B. Fernandes, L.T. Galindo, B.B. de Souza, F.A. Duarte, F.L.V. Visani, I.S. Negreiros, N. Afonso, P.N. Aguiar, T. Vilasboas Reis, C.M. De Cerqueira Mathias, L.M. Da Silva, C. Leslin, M.G. Zalis, C.G.M. Ferreira
Journal: Journal of Thoracic Oncology (2023)
69P The effect of inflammatory-nutritional prognostic scoring system (INPS) on treatment response and prognosis in patients with metastatic NSCLC as second-line treatment with nivolumab
Authors: M. Keskinkilic, F. Yalcin Kucukbayrak, G. Polat, D. Delibalt, H. Ellidokuz, I. Oztop
Journal: Journal of Thoracic Oncology (2023)
191P ROS1 fusions in resected stage I-III adenocarcinoma (ADC): A Lungscape ETOP study
Authors: E-J.M. Speel, T. Radonic, U. Dafni, E. Thunnissen, J.H. Rüschoff, J. Kowalski, K.M. Kerr, L. Bubendorf, I. Sansano Valero, L. Joseph, A. Navarro, K. Monkhorst, L.B. Madsen, J. Hernandez Losa, W. Biernat, T. Dellaporta, R. Kammler, S. Peters, R.A. Stahel, S.P. Finn
Journal: Journal of Thoracic Oncology (2023)
7MO Sotorasib in KRAS G12C-mutated advanced non-small cell lung cancer (aNSCLC): Overall survival (OS) data from the global expanded access program (EAP study-436)
Authors: S. Novello, N. Maimon, J.P. Stevenson, W. Petty, C.G.M. Ferreira, I. Morbeck, A. Zer, J.R. Bauman, S. Kalmadi, C. Xia, A. Meloni, T. Varrieur, M. Awad
Journal: Journal of Thoracic Oncology (2023)
185P Influence of corticosteroids and antibiotics on the microbiota and the efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC)
Authors: M. Zapata García, R. Lastra, A. Moratiel Pellitero, M. Gascon Ruiz, A. Sesma Goñi, E. Quilez Bielsa, M. Cruellas Lapena, J.R. Paño-Pardo, R. Del Campo, M.I. Torres Ramon, A. Yubero Esteban, A. Ramírez-Labrada, E.M. Gálvez, J. Pardo, M.D. Isla Casado
Journal: Journal of Thoracic Oncology (2023)
9MO Profile of immunorecognition related markers including HLA-1 expression to predict response to immunocheckpoint inhibitors in non-small cell lung cancer
Authors: M. Saigi, J.L. Mate, E. Carcereny, A.M. Esteve Gomez, F. Andreo, A. Martinez-Cardús, M. Cucurull Salamero, C. Centeno, E. Pros, A. López, G. Cerdá, M.T. Moran Bueno, A. Hernandez Gonzalez, M. Domenech Vinolas, A.M. Muñoz-Mármol, M. Sánchez-Céspedes
Journal: Journal of Thoracic Oncology (2023)
13MO Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab ± chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05 phase II study)
Authors: N. Isambert, T. Nagy, M. Ravoire, D. Rodriguez-Abreu, J.L. Gonzalez-Larriba, C.H. Huang, L. Paz-Ares, J. Roubec, F. Rey, G. Robinet, A. Onn, S. Shamai, S. Bensfia, C. Soufflet, A. Chevance, R. Veillon
Journal: Journal of Thoracic Oncology (2023)
67P Blood cell gene expression and clinical characteristics in advanced non-small cell lung cancer with immune-related adverse events
Authors: L. Daniello, M. Elshiaty, F. Lusky, M. Blasi, M.A. Schneider, F. Bozorgmehr, R. Shah, D. Kazdal, A. Angeles, S. Liersch, F. Eichhorn, M. Allgäuer, F. Janke, H. Bischoff, M. Thomas, H. Sültmann, A. Stenzinger, P. Christopoulos
Journal: Journal of Thoracic Oncology (2023)
205P Modelling of NSCLC aPD1 responses in bronchoscopc biopsies on chip (bronchoBOCs)
Authors: Katerina Douka, M. Frantzi, M. Matthaiakaki-Panagiotaki, F. Mazzoni, S. Fancelli, S. Pilozzi, P. Ulivi, L. Antonuzzo, A. Delmonte, V. Roman, I. Sigala, N. Gianniou, I. Kalomenidis, M. Makridakis, A. Vlahou, H. Mischak, M. Tsoumakidou
Journal: Journal of Thoracic Oncology (2023)
55P Real-world monitoring of hybrid dosing of pembrolizumab in stage IV non-small cell lung cancer in the Netherlands
Authors: E. Dronkers, E. van Geffen, C. Bekkers, A. Sobels, R. van Drie-Pierik, A. Eldering-Heldens, J. Zwaveling, J. Eijsink, H.J.M. Smit, D. Hilarius
Journal: Journal of Thoracic Oncology (2023)
81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study
Authors: M.L. Johnson, S-H.I. Ou, E. Felip, C. Baik, B. Besse, J. Mazieres, D.R. Camidge, S. Gadgeel, A. Drilon, Y.Y. Elamin, G. Liu, J.E. Reuss, T. Kehrig, H.E. Pelish, V. Zhu, J.J. Lin
Journal: Journal of Thoracic Oncology (2023)
83TiP A phase II study of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, alone and in combination with nivolumab in adult patients with metastatic NSCLC who had prior disease progression on or are intolerant to a PD-1/L1, EGFR, or ALK inhibitor
Authors: G. Dy, M. Alexander, D.R. Camidge
Journal: Journal of Thoracic Oncology (2023)
170P Preliminary results from LUMINANCE: A phase IIIb, single-arm study of 1L durvalumab (D) + platinum-etoposide (EP) for patients with extensive-stage SCLC (ES-SCLC)
Authors: N. Reinmuth, F. de Marinis, N. Leighl, S. Sadow, K. Davey, M. Özgüroğlu
Journal: Journal of Thoracic Oncology (2023)
Role of a Novel Self-Reported Questionnaire for Frailty Assessment in HFpEF
Authors: Ambarish Pandey, Dalane W. Kitzman
Journal: JACC Heart Failure (2023)

The U.S. heart allocation system ranks candidates with only 6 treatment-based categorical “statuses” and ignores many objective patient characteristics.This study sought to determine the effectiveness of the standard 6-status ranking system and several novel prediction models in identifying the most urgent heart transplant candidates.The primary outcome was death before receipt of a heart transplant. The accuracy of the 6-status system was evaluated using Harrell’s C-index and log-rank tests of Kaplan-Meier estimated survival by status for candidates listed postpolicy (November 2018 to March 2020) in the Scientific Registry of Transplant Recipients data set. The authors then developed Cox proportional hazards models and random survival forest models using prepolicy data (2010-2017). The predictor variables included age, diagnosis, laboratory measurements, hemodynamics, and supportive treatment at the time of listing. The performance of these models was compared with the candidate’s 6-status ranking in the postpolicy data.Since policy implementation, the 6-status ranking at listing has had moderate ability to rank-order candidates (C-index: 0.67). Statuses 4 and 6 had no significant difference in survival (P = 0.80), and status 5 had lower survival than status 4 (P < 0.001). Novel multivariable prediction models derived with prepolicy data ranked candidates correctly more often than the 6-status rankings (Cox proportional hazards model C-index: 0.76; random survival forest model C-index: 0.74). Objective physiologic measurements, such as glomerular filtration rate, had high variable importance.The treatment-based 6-status heart allocation system has only moderate ability to rank-order candidates by medical urgency. Predictive models that incorporate physiologic measurements can more effectively rank-order heart transplant candidates by urgency.
Mapping human adult hippocampal neurogenesis with single-cell transcriptomics: Reconciling controversy or fueling the debate?
Authors: Giorgia Tosoni, Dilara Ayyildiz, Julien Bryois, Will Macnair, Carlos P. Fitzsimons, Paul J. Lucassen, Evgenia Salta
Journal: Neuron (2023)

The notion of exploiting the regenerative potential of the human brain in physiological aging or neurological diseases represents a particularly attractive alternative to conventional strategies for enhancing or restoring brain function. However, a major first question to address is whether the human brain does possess the ability to regenerate. The existence of human adult hippocampal neurogenesis (AHN) has been at the center of a fierce scientific debate for many years. The advent of single-cell transcriptomic technologies was initially viewed as a panacea to resolving this controversy. However, recent single-cell RNA sequencing studies in the human hippocampus yielded conflicting results. Here, we critically discuss and re-analyze previously published AHN-related single-cell transcriptomic datasets. We argue that, although promising, the single-cell transcriptomic profiling of AHN in the human brain can be confounded by methodological, conceptual, and biological factors that need to be consistently addressed across studies and openly discussed within the scientific community.
β-secretase 1 overexpression by AAV-mediated gene delivery prevents retina degeneration in a mouse model of age-related macular degeneration
Authors: Xiaoping Qi, Carolina Francelin, Sayak Mitter, Sanford L. Boye, Hongmei Gu, Judith Quigley, Maria B. Grant, Michael E. Boulton
Journal: Molecular Therapy (2023)

We reported previously that β-site amyloid precursor protein cleaving enzyme (BACE1) is strongly expressed in the normal retina and that BACE1
Contents
Journal: Journal of the American College of Cardiology (2023)

Mineralocorticoid receptor antagonists (MRAs) are underprescribed for patients with heart failure with reduced ejection fraction (HFrEF).This study sought to compare effectiveness of 2 automated, electronic health record–embedded tools vs usual care on MRA prescribing in eligible patients with HFrEF.BETTER CARE-HF (Building Electronic Tools to Enhance and Reinforce Cardiovascular Recommendations for Heart Failure) was a 3-arm, pragmatic, cluster-randomized trial comparing the effectiveness of an alert during individual patient encounters vs a message about multiple patients between encounters vs usual care on MRA prescribing. This study included adult patients with HFrEF, no active MRA prescription, no contraindication to MRAs, and an outpatient cardiologist in a large health system. Patients were cluster-randomized by cardiologist (60 per arm).The study included 2,211 patients (alert: 755, message: 812, usual care [control]: 644), with average age 72.2 years, average ejection fraction 33%, who were predominantly male (71.4%) and White (68.9%). New MRA prescribing occurred in 29.6% of patients in the alert arm, 15.6% in the message arm, and 11.7% in the control arm. The alert more than doubled MRA prescribing compared to usual care (relative risk: 2.53; 95% CI: 1.77-3.62; P < 0.0001) and improved MRA prescribing compared to the message (relative risk: 1.67; 95% CI: 1.21-2.29; P = 0.002). The number of patients with alert needed to result in an additional MRA prescription was 5.6.An automated, patient-specific, electronic health record–embedded alert increased MRA prescribing compared to both a message and usual care. These findings highlight the potential for electronic health record–embedded tools to substantially increase prescription of life-saving therapies for HFrEF. (Building Electronic Tools to Enhance and Reinforce Cardiovascular Recommendations—Heart Failure [BETTER CARE-HF]; NCT05275920)
86P KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma
Authors: D. Marinelli, E. Melis, A. Torchia, D. Forcella, A. Botticelli, P. Visca, S. Buglioni, F. Facciolo, F.T. Gallina
Journal: Journal of Thoracic Oncology (2023)
50P Patient-reported outcomes in non-small cell lung cancer patients receiving immunotherapy monotherapy: Analysis from enhanced, EHR-facilitated cancer symptom control (E2C2) pragmatic clinical trial
Authors: B. Liu, V. Lam, D. Pachman, K. Ruddy, O. Burke, P. Lingamaneni, Y. Yu, G. Jiang, A. Cheville, K. Leventakos
Journal: Journal of Thoracic Oncology (2023)
197P Combining stereotactic body radiation and low-dose radiation (EclipseRT) with PD-1 inhibitor in mice models and patients with bulky tumor
Authors: R. Luo, Z. Su, K. Kang, M. Yu, X. Zhou, Y. Wu, Z. Yao, W. Xiu, Y. Yu, L. Zhou, F. Na, Y. Li, X. Zhang, B. Zou, F. Peng, J. Wang, J. Xue, Y. Gong, Y. Lu
Journal: Journal of Thoracic Oncology (2023)